AstraZeneca and Idoven launch CONCERTO to advance early amyloidosis diagnosis. Read more here.
We believe that the application of AI in healthcare is one of the most transformational shifts of our time. Our mission is to make that happen, faster, in the fight against the leading killer globally: cardiovascular disease.
At Idoven, we believe technology should do more than analyze heartbeats—it should help save lives.
Our journey began when a cardiologist and a machine learning scientist came together to tackle a critical question: Can we detect heart disease before it strikes?
As we explored existing technology, we saw major challenges—data locked in proprietary ECG formats, outdated software unable to adapt, and AI models that failed to make a real impact in clinical settings.
Healthcare needed a new approach, one that combined medical expertise, engineering, and artificial intelligence to power the next generation of cardiovascular diagnostics. That’s why we founded Idoven.
Idoven is founded to translate a decade of cardiology and AI research into Willem™, its AI-powered platform for EGC analysis.
First strategic collaborations with Google and Banco Santander for remote cardiac monitoring
Selected for the Lilly & UnLtd Accelerator
Granted the EU Seal of Excellence in 2020, 2021 and 2022
Receives NEOTEC funding from Spain’s CDTI
Iker Casillas joins Idoven as brand ambassador and investor
Raises €2M in seed funding with Wayra, Accel Starter Programme and business angels
Secures €6.5M through the EIC Accelerator
Launches the WILLEM Clinical Trial
Joins MAESTRIA, a €14M Horizon Europe–funded, 17-partner consortium developing the first AI platform for atrial cardiomyopathy, AF, and stroke diagnosis.
Wins “Most Disruptive Startup” and “Best Health Startup” at South Summit
Closes €18.5M Series A co-led by Insight Partners and Northzone
Joins ARISTOTELES, a €6M Horizon Europe–funded, 18-partner consortium developing trustworthy AI for chronic disease management, initially focused on atrial fibrillation.
Named among the Top 150 Digital Health Companies worldwide by CB Insights.
Begins collaboration with Abbott to apply
Willem™ AI to ICM's episode classification
Leads ASSIST, a €1.5M EIT Health–funded project to improve heart attack diagnosis
.jpg)
Pau Gasol joins Idoven as brand ambassador and investor
Named among the Top 50 Digital Health Companies by CB Insights.
Willem™ receives CE Mark Class IIa with the broadest device-approved scope on the market, covering 22 cardiac patterns.
.svg)
Dr. Pablo García-Pavía
joins Idoven as Medical Advisor, contributing his expertise in cardiac amyloidosis.
Prof. Gregory Y.H. Lip
recognised for his work in atrial fibrillation, joins Idoven as Medical Advisor.
Leads FAITHFUL, a €1.7M EIT Health–funded consortium with AstraZeneca focused on early heart failure detection
.jpg)
Launches the #DonateYourHeartbeats app for cardiovascular research.
Peer-reviewed study demonstrating 96.4% accuracy of Willem™ for AI-based AF detection from AliveCor single-lead ECGs.
Launches CONCERTO with AstraZeneca to advance early diagnosis of cardiac amyloidosis
.jpg)
.png)
.png)
.png)
